A Phase 3, Randomized, Open-Label Study of Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy
A Phase 3, Randomized, Open-Label Study of Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy
This study will be conducted to compare Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy.
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined Inclusion/Exclusion Criteria may apply.
Innsbruck, 06020, Austria
Godinne-mont, 05530, Belgium
Woluwe-Saint-Lambert, 01200, Belgium
Ostrava-poruba, 708 52, Czechia
Prague, 12808, Czechia
Helsinki, 00290, Finland
Lille, 59037, France
Villejuif, 94805, France
Athens, 12462, Greece
RIO Patras, 26504, Greece
Thessaloniki, 57010, Greece
Bologna, 40138, Italy
Brescia, 25123, Italy
Catania, 95125, Italy
Milan, 20132, Italy
Amsterdam, 1081 HV, Netherlands
Leiden, 2333 ZA, Netherlands
SAN Sebasttian, 20014, Spain
Valencia, 46010, Spain
Valencia, 46026, Spain
Gothenburg, 41650, Sweden
Stockholm, 14186, Sweden
Geneva, 01205, Switzerland
Leicester, LE1 5WW, United Kingdom